{"id":13153,"date":"2025-07-11T18:15:08","date_gmt":"2025-07-11T18:15:08","guid":{"rendered":"https:\/\/www.vdh.virginia.gov\/disease-prevention\/?p=13153"},"modified":"2025-07-11T18:15:38","modified_gmt":"2025-07-11T18:15:38","slug":"ddp-e-bulletin-july-2025","status":"publish","type":"post","link":"https:\/\/www.vdh.virginia.gov\/disease-prevention\/2025\/07\/11\/ddp-e-bulletin-july-2025\/","title":{"rendered":"DDP E-Bulletin: July 2025"},"content":{"rendered":"
\n
\n\t\t\"July\n\t<\/div>\n\n<\/div><\/div><\/div><\/div><\/div>

Hep Free Virginia: Virginia\u2019s Hepatitis Elimination Plan<\/h1><\/h3>\n
\n\t

DDP has collaborated with a range of statewide stakeholders to create <\/span><\/span>Hep Free <\/span>VA<\/span>,<\/span><\/span> Virginia\u2019s<\/span> Viral Hepatitis Elimination Plan<\/span>.\u00a0 <\/span>The plan aims to <\/span>eliminate<\/span> viral hepatitis in Virginia by 2030 by achieving six main goals.<\/span><\/span>\u00a0<\/span><\/p>\n<\/div>\n<\/div><\/div><\/div>

\n\t\t\t\n\t\t\n\t\t\t\n\t\t\tRead more about Hep Free VA\t\t<\/span>\n\t\t\t<\/a>\n\t<\/div>\n<\/div><\/div><\/div>
\n
\n\t\t\"\"\n\t<\/div>\n\n<\/div><\/div><\/div><\/div><\/div>

There\u2019s a New PrEP Option!<\/h1><\/h3>\n
\n\t

Lenacapavir was approved by the Food and Drug Administration (FDA) on June 18 for use as HIV Pre-Exposure Prophylaxis (PrEP).\u00a0 It is an injection given twice a year. It will be sold under the brand name Yeztugo (yez-TOO-go).\u00a0 Clinical trials proved the drug blocked HIV in 100% of >2,000 cisgender women who\u2019d received it in the PURPOSE 1 trial<\/a>.\u00a0 The drug blocked HIV in nearly 100% of>2,000 cisgender men and gender-diverse persons who\u2019d received it in the PURPOSE 2 trial<\/a>.<\/p>\n<\/div>\n<\/div><\/div>

\n\t\t\t\n\t\t\n\t\t\t\n\t\t\tLearn more about the new PrEP option\t\t<\/span>\n\t\t\t<\/a>\n\t<\/div>\n<\/div><\/div><\/div><\/div><\/div>
\n
\n\t
\n

 <\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>

Hotline Discontinuing Mailing of Print Materials <\/h1><\/h3>\n
\n\t

DDP will be discontinuing its library\/warehouse of print materials for health districts and community partners. Educational materials and resources will instead be available on the DDP website in electronic format for download. These electronic resources can be printed by agencies or shared online.<\/p>\n

Agencies can continue to order print materials<\/a> that are currently in stock until September 30, 2025.<\/p>\n

For any questions about this transition, please contact the Disease Prevention Hotline at std-hivhotline@vdh.virginia.gov<\/a> or (800) 533-4148.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

\n
\n\t
\n

 <\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

Hepatitis Program Poster Presented at CSTE Conference <\/h1><\/h3>\n
\n\t

In 2024, DDP launched a pilot Hepatitis \"HepatitisC Virus (HCV) Genomic Surveillance program in the Southwest health region.\u00a0 The program is intended to show effective integration of data for identifying transmission networks, specifically, genomic and epidemiological data.\u00a0 This approach aims to support targeted public health responses and interventions.\u00a0 By October 1, 2024, DDP analyzed 137 cases using the CDC-developed Global Hepatitis Outbreak Surveillance Technology (GHOST) bioinformatics system.\u00a0 It identified eight single-linkage clusters and two multi-linkage, jurisdiction-spanning clusters.\u00a0 Notably, mixed infections were detected within both multi-linkage clusters.\u00a0 This indicated recent transmission events.<\/p>\n

Findings highlighted that targeted genomic surveillance could detect active HCV transmission networks.\u00a0 Furthermore, combining genomic data with epidemiological surveillance enables more precise allocation of resources and focused public health action.<\/p>\n

DDP\u2019s Tabatha Heaton<\/strong> presented these results as a poster at the Council of State and Territorial Epidemiologists (CSTE) 2025 Conference.<\/p>\n

For more information, contact Tabatha at tabatha.heaton@vdh.virginia.gov<\/a>.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>

\n
\n\t
\n

 <\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

VDH Mpox Webpages Now Live! <\/h1><\/h3>\n
\n\t

The DDP Mpox webpages are now live!<\/p>\n

DDP has taken ownership of the mpox webpages for VDH.\u00a0 The new URL for the main mpox page is https:\/\/www.vdh.virginia.gov\/disease-prevention\/mpox<\/a>.\u00a0 However, the vanity URL of vdh.virginia.gov\/mpox<\/a> will continue to work and will redirect to the new mpox page.<\/p>\n

There is also an mpox resources page<\/a> with print, social media, video, and toolkit resources for healthcare providers and partner agencies.<\/p>\n

For any questions about the new pages or to report any issues, please contact Chris Barnett<\/strong>, Public Relations Coordinator, at christopher.barnett@vdh.virginia.gov<\/a>.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

\n
\n\t
\n

 <\/p>\n<\/div>\n<\/div><\/div><\/div><\/div>

New Peer-Reviewed Paper on Trends in ADAP Support<\/h1><\/h3>\n
\n\t

NASTAD and the University of Virginia have shared a new peer-reviewed paper published by the American Journal of Public Health.\u00a0 The title of the paper is \u201cTrends in AIDS Drug Assistance Program Support for People With HIV, by Age, Sex, Race, and US Region, 2008-2021.\u201d\u00a0 Dr. Kathleen McManus of UVA is the lead author and principal investigator of a research project conducted in partnership with NASTAD.\u00a0 This longitudinal study provides an analysis of the evolution of ADAPs.\u00a0 It does this through examining 14 years of state-level data, beginning in 2008.<\/p>\n

Key findings include:<\/p>\n